A combination of durvalumab and standard first-line chemotherapy has shown promise for the management of untreated patients with advanced mesothelioma unsuitable for surgery. The phase 2 single-arm Australian study, published in The Lancet Oncology, is the first clinical trial reporting on the combination of a checkpoint inhibitor and standard chemotherapy in malignant pleural mesothelioma. The ...
Advanced mesothelioma: frontline chemoimmunotherapy shows promise in DREAM trial
By Mardi Chapman
16 Sep 2020